HomeLegal DirectoryFDA GMLP Principles

In effect Moderate protection

FDA/Health Canada/MHRA Good Machine Learning Practice Guiding Principles

United States · FDA/HC/MHRA GMLP Guiding Principles (Oct. 27, 2021)

Joint guiding principles by FDA, Health Canada, and the UK MHRA on safe development of ML-enabled medical devices. Updated by FDA's 2024 Transparency Guiding Principles.

Technical detail

10 GMLP guiding principles cover good software engineering, representative datasets, independence of training/test data, model-design tailored to data and clinical use, focus on the performance of the human-AI team, clinically meaningful test performance, training data quality, transparency, monitoring of deployed performance, and clear cybersecurity practices.

Who is protected: Patients whose care involves ML medical devices

Who must comply: Manufacturers of ML medical devices

Key facts

JurisdictionUnited States
LevelFederal
StatusIn effect
Protection strengthModerate protection
Effective date2021-10-27
Enacted2021-10-27
CitationFDA/HC/MHRA GMLP Guiding Principles (Oct. 27, 2021)
Enforced byFDA / CDRH (via existing FDCA authorities)
Private right of actionNo — agency enforcement only
PenaltiesFDCA enforcement
Topicshealthcare AI · automated decision-making
Last verified2026-06-16
Official sourceGood Machine Learning Practice for Medical Device Development — FDA ↗

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction — every entry must carry a verifiable official source.